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The effects of sandostatin (Octreotide, SMS 201-995) infusion on
splanchnic and hepatic blood flow in an experimental model of hepatic
metastases
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Univ ersitv Departments ofSurger., Glasgowt RoYal InfirmarY and Royal Liverpool Hospital, UK.
Summaai Manipulation of hepatic blood flow may improse drug delivery to hepatic tumour. Somatostatin
and its long acting analogues are known to elicit effects upon hepatic and splanchnic blood flow in
experimental animals and patients with portal hypertension. This study investigates the effects of SMS
201-995 (sandostatin) infusion on hepatic. splanchnic and tumour blood flow in an experimental model of
liver metastases.
Hepatic tumour was induced by the intraportal inoculation of 106 HSN sarcoma cells and blood flou-
measured using the dual reference microsphere method before and after infusion of SMS 201-995.
There was a significant decrease in hepatic artenral flow and a significant increase in the tumour:liver blood
flow ratio associated with a marked reduction in blood flow to normal hepatic parenchyma. Portal *-enous
inflow and tumour blood flou- were not significantly affected.
SMS 201-995 infusion mav lead to preferential delivery of concomitantly injected cytotoxic drugs to hepatic
tumour. In addition. the reduction in growth of hepatic tumour mav be due to a reduction in nutritive. arterial
blood flow to hepatic tumour.
Up to 600o of patients with colorectal cancer develop liser
metastases which are rarely surgically resectable (Finlav et
al.. 1982) and systemic or regional chemotherapy is often
used to treat these patients (Kemeney et al.. 1987). The
extraction of regionally delivered drug by the liver is inverse-
ly proportional to hepatic blood flow (Sigurdson et al.. 1986)
and as many hepatic tumours are hypovascular this may
limit delivery of the chemotherapeutic drug to tumour and
may. in part. explain the relatively poor response rates to
chemotherapy
Manipulation of hepatic blood flow by vasoactiye agents
may therefore improve extraction of drug by the liver. In
addition, an alteration in the relative blood flow distribution
between the normal liver parenchyma and hepatic tumour
may also improve drug delivery to hepatic tumour.
Somatostatin and its long acting analogue sandostatin
(Octreotide. SMS 201-995). are known to elicit effects upon
hepatic and splanchnic blood flow in experimental animals
and patients with cirrhosis and portal hypertension (Keller et
al.. 1978: Price et al.. 1985: Sonnenbert et al.. 1981). We have
therefore investigated the effects of SMS 201-995 infusion
on hepatic. splanchnic and tumour blood flow in an experi-
mental model of hepatic metastases.
Methods
Tumour induction
HSN sarcoma cells were grown in Dulbecco's modified
Eagles Medium (Sigma. UK) supplemented with 1000o foetal
calf serum at 37°C in an incubator. Hepatic tumour was
induced by the intra-portal inoculation of 106 HSN sarcoma
cells, trypsinised from a confluent monolayer. in male Hood-
ed Lister rats. Our previous studies have demonstrated that
discrete hepatic tumour is present 3 weeks after the inocula-
tion of these tumour cells (Hemingway et al.. 1991b).
Hepatic haemodvnamics
Organ blood flow, before and after the infusion of SMS
201-995 was measured using a dual microsphere technique.
In brief. 10 tumour bearing rats. 250 g weight. were anaes-
thatised with intraperitoneal sodium pentobarbitone. One
hundred thousand 5'Co microspheres (Nentrac. Dupont. Ger-
many) were suspended in normal saline with 0.01% Tween in
a volume of 0.3 ml and injected over 29 s via a cannula
(Portex. Hv-the. UK) screened into position in the left ven-
tricle using a Siemens Image Intensifier (Siemens. Germans;)
via the right carotid artery. A reference sample of blood was
withdrawn at a rate of mlmin' from the right femoral
artery starting 10 s before and continuing for 40 s after the
microsphere injection. The withdrawal rate was constant at
1 ml min-. Arterial blood pressure was measured using a
strain gauge transducer and pen recorder attached to a can-
nula in the left femoral arten-. The animals received an
intravenous bolus of SMS 201-995. 41gg kg-'. in a volume
of 80 tl. followed by a continuous infusion at a rate of
4 pLg kg-'h-' in a volume of 0.2ml min'- for 10 min. At the
end of the infusion the blood flow measurements were repeat-
ed by a further intraventricular bolus injection of 5'Cr micro-
spheres as described previously for 5-Co. and a second
reference sample obtained. Five minutes later the animals
were humanely killed, the organs were removed, weighed.
placed in vials and counted on a well gamma counter along
with the reference samples of blood. Counts were corrected
for Compton effect down scatter into the "'Cr channel.
4naly sis ofdata
Organ blood flow was calculated using the method of
McDeVitt and Nies (1976).
Organ blood flow=
activitv in each sample (c.p.m.)
activity in reference sample (c.p.m.)
x withdrawal rate
Hepatic arterial flow was determined from the counts in the
liver. Portal venous inflow was determined from counts in the
splanchnic organs draining into the portal vein and hepato-
splanchnic flow as the sum of hepatic arterial and portal
venous inflow. Hepatic tumour was carefully dissected from
the surrounding normal hepatic parenchyma. weighed and
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counted separately. to enable blood flow to tumour and
normal liver to be calculated. Each animal acted as its own
control since we have previously demonstrated that infusion
of saline at a rate of 0.2 ml min-' for 10 min into tumour
bearing rats does not significantly affect blood flow (Heming-
way et al.. 1991a). Animals were discarded from further
analysis if blood flow between the right and left kidneys
differed by greater than 10% since this indicates inadequate
ventricular mixing of microspheres. and if any organ con-
tained less than 400 particles to ensure adequate counting
statistics. The hepatic replacement by tumour was calculated
as the weight of tumour tissue as a percentage of the total
liver weight. The effect of SMS 201-995 infusion on hepatic
blood flow was compared using the non-parametric Wilcox-




All animals inoculated with tumour cells developed overt
hepatic tumours which were distributed throughout the hepa-
tic parenchvma. The median percentage hepatic replacement
by tumour was 1501o by weight (range 7% to 30%).
S!stemic blood pressure
SMS 201-995 had no sinificant effect upon systemic arterial
blood pressure (110(10) mmHg before infusion. 105(15)
mmHg after infusion).
Organ blodflowr
Infusion of SMS 201-995 resulted in a significant (P=
0.025) decrease in hepatic artenral flow from 4.55 ± 4.24
before to 1.95 (0.97) ml min-' (Table I). However. portal
venous inflow wAas not significantly altered from its pre-
infusion rate (Table I). but hepatosplanchnic flow did fall
significantly (P = 0.032) from 9.7(8.77) ml min-' to 7.0
(1.99) ml min' after SMS infusion (Table I). Tumour blood
flow was reduced from 0.28(0.18) ml min-' g-1 to 0.10(0.08)
although the reduction was not statistically significant. In
contrast. blood flow to normal hepatic parenchvma was
significantly reduced (P = 0.014) from 0.37(0.28) ml minm
g-I to 0.16(0.09) ml min-' g'. The tumour:liver blood flow
ratio was significantly increased (P = 0.042) from 0.55(0.47)
to 0.75(0.62) (Table I).
Discusion
We have previously demonstrated that there are significant
alterations in liver blood flow in the presence of hepatic
tumour (Hemingway et al.. 1991b). In the present study using
rats with hepatic tumour derived from the intraportal inocu-
lation of HSN sarcoma cells hepatic arterial flow contributed
almost 50% of the total liver blood flow before SMS 201-
995 infusion. compared with its usual 26% in normal
animals. These results therefore confirm our previous obser-
vations that the growth and development of hepatic tumour
is associated with marked changes in hepatic haemodyna-
mics. In addition. these tumours were hypovascular with a
mean tumour:liver blood flow ratio of 0.55:1.
Whilst there are some conflicting reports on the effects of
somatostatin and SMS 201-995 in expenrmental animals and
in man. the consensus of opinion is that in portal hyperten-
sion. the naturally occurring hormone and its synthetic
analogue have some effects (Kleber et al.. 1988: Kravitz et
al.. 1988: Jenkins et al.. 1985a; 1985b). For example. previous
studies in cirrhotic patients have demonstrated that somato-
statin at a dose of 250 tg h-' reduces total hepatic blood
flow (Keller et al.. 1978). Similarly. studies in dogs have
demonstrated that somatostatin infusion reduces portal
venous inflow by up to 30% (Price et al.. 1985). Vasoactive
agents can have profound effects upon hepatic blood flow in
man and animals with hepatic tumour (Hemingway et al..
1991c: Sasaki et al.. 1985). This is confirmed in this study
which clearly demonstrates a significant reduction in both
hepatic arterial flow and results in a decrease in total hepato-
splanchnic flow when SMS 201-995 was infused. The reduc-
tion in hepatic arterial flow was associated with a rise in the
tumour:liver blood flow ratio which was due predominantly
to a fall in the arterial supply to the surrounding normal
hepatic parenchyma. with no significant change in the
measured tumour blood flow. This confirms the observations
of Mattson et al. (1977) who reported that the blood vessels
of tumours were immature. lacking muscular or nervous
elements. and thus unable to respond to vasoactive agents.
Table I The effects of SMS 201-995 on hepatic arterial flow. portal venous inflow.
hepato-splanchnic flow. liver and tumour flow and tumour:liver blood flow ratio in rats with
overt HSN hepatic tumours
Hepatic Portal Hepato
arterial venous splanchnic Liver Tumour
flow floet flow floe floh Tumour.:liver
.4nimal mlrmin- mlmin- mlmin- mlrmin-m]g! mimin-'g- flog ratio
1 2.61 4.07 6.68 0.118 0.145 0.814
2.64 5.24 7.88 0.107 0.149 0.72
9.61 9.15 18.76 0.447 0.767 0.58
1.93 6.91 3.84 0.12 0.153 0.78
3 7.97 9.26 17.23 0.28 0.53 0.52
1.56 5.08 6.62 0.048 0.105 0.45
4 10.47 7.48 17.55 0.272 0.939 0.29
1.73 6.11 7.84 0.037 0.157 0.23
5 4.28 4.51 8.79 0.062 0.314 0.2
4.27 5.1 9.37 0.147 0.3 0.49
6 4.81 5.45 10.26 0.125 0.36 0.34
2.28 5.11 7.39 0.072 0.17 0.42
7 3.17 3.96 7.13 0.11 0.209 0.526
1.67 5.75 7.42 0.085 0.102 0.83
8 6.39 7.67 14.06 0.3 0.41 0.73
1.44 4.52 5.96 0.096 0.09 1.07
9 3.88 5.26 9.14 0.286 0.255 1.12
4.08 6.65 10.73 0.38 0.266 1.43
10 3.73 4.73 8.46 0.312 0.386 0.808
1.97 3.88 5.83 0.447 0.201 2.23
The first ofeach pair ofvalues is the pre-infusion value and the second is the post-infusion
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Hepatic arterial vasoconstriction takes place predominantly
in the blood vessels of the normal hepatic parenchyma lead-
ing to an increase in the relative blood flow to hepatic
tumour. This may be of clinical value as it may lead to
preferential delivery of concomitantly administered cytotoxic
agents to tumours with relative sparing of normal hepatic
parenchyma.
In previous studies we have observed that SMS 201-995
inhibits the growth of hepatic tumour derived from the intra-
portal inoculation of Walker carcinosarcoma cells which was
associated with a marked stimulation of the reticuloendo-
thelial system (Nott et al.. 1989). Since the RES comprises
the bodv s natural defence system against tumour cells. it was
suggested that the stimulation of the Kuppfer cells may have
been in part responsible for the inhibition of growth of the
hepatic tumour. Although comparisons of liver blood flow
were made between the two groups in that study. firm con-
clusions could not be made regarding the effect of SMS
201-995 on liver blood flow and its effect on tumour growth
since there was very little tumour in the liver in the group
treated with sandostatin at the end of the 3 week period. The
results of this study however suggest that SMS 201-995. by
reducing hepatic arterial flow may well influence the growth
of hepatic tumour which derives its nutritive blood supply
almost entirely from the hepatic artery.
This study was supported by the Cancer Research Campaign and the
North West Cancer Research Fund. The HSN tumour was a gift of
Dr S-A. Eccles. and SMS 201-995 a gift of Sandoz Pharmaceuticals.
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